Title: Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
Authors: Van de Veire, Sara ×
Stalmans, Ingeborg
Heindryckx, Femke
Oura, Hajimu
Tijeras-Raballand, Annemilai
Schmidt, Thomas
Loges, Sonja
Albrecht, Imke
Jonckx, Bart
Vinckier, Stefan
Van Steenkiste, Christophe
Tugues, Sonia
Rolny, Charlotte
De Mol, Maria
Dettori, Daniela
Hainaud, Patricia
Coenegrachts, Lieve
Contreres, Jean-Olivier
Van Bergen, Tine
Cuervo, Henar
Xiao, Wei-Hong
Le Henaff, Carole
Buysschaert, Ian
Masouleh, Behzad Kharabi
Geerts, Anja
Schomber, Tibor
Bonnin, Philippe
Lambert, Vincent
Haustraete, Jurgen
Zacchigna, Serena
Rakic, Jean-Marie
Jimenez, Wladimiro
Noel, Agnes
Giacca, Mauro
Colle, Isabelle
Foidart, Jean-Michel
Tobelem, Gerard
Morales-Ruiz, Manuel
Vilar, Jose
Maxwell, Patrick
Vinores, Stanley A
Carmeliet, Geert
Dewerchin, Mieke
Claesson-Welsh, Lena
Dupuy, Evelyne
Van Vlierberghe, Hans
Christofori, Gerhard
Mazzone, Max
Detmar, Michael
Collen, Desire
Carmeliet, Peter #
Issue Date: Apr-2010
Publisher: Cell press
Series Title: Cell vol:141 issue:1 pages:178-190
Abstract: Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
ISSN: 0092-8674
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Research Group Ophthalmology
Section Woman - Miscellaneous (-)
Vesalius Research Centre (-)
Molecular and Vascular Biology
Clinical and Experimental Endocrinology
Gynaecological Oncology
Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven Centre for Cancer Biology) (+)
Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven Centre for Cancer Biology) (+)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.pdf Published 2290KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science